Cargando…
Clinical Utility of Plasma-Based Comprehensive Molecular Profiling in Advanced Non–Small-Cell Lung Cancer
Comprehensive molecular profiling (CMP) plays an essential role in clinical decision making in metastatic non–small-cell lung cancer (mNSCLC). Circulating tumor DNA (ctDNA) analysis provides possibilities for molecular tumor profiling. In this study, we aim to explore the additional value of central...
Autores principales: | Schouten, Robert D., Vessies, Daan C. L., Bosch, Linda J. W., Barlo, Nicole P., van Lindert, Anne S. R., Cillessen, Saskia A. G. M., van den Broek, Daan, van den Heuvel, Michel M., Monkhorst, Kim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277301/ https://www.ncbi.nlm.nih.gov/pubmed/34632253 http://dx.doi.org/10.1200/PO.20.00450 |
Ejemplares similares
-
Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022) -
Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II–IIIA NSCLC patients
por: Vessies, Daan C. L., et al.
Publicado: (2022) -
Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022) -
Cell-free DNA in the supernatant of pleural effusion can be used to detect driver and resistance mutations, and can guide tyrosine kinase inhibitor treatment decisions
por: Hummelink, Karlijn, et al.
Publicado: (2019) -
Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
por: Janssen, Julie M., et al.
Publicado: (2022)